Skip to main content Skip to search Skip to main navigation

ICH: Plans to harmonize with PIC/S and WHO

The International Council for Harmonisation (ICH) has made the Minutes of the ICH Assembly Meeting in Singapore, in November 2019, publicly available. In contrast to the already published press release (we reported), the meeting minutes include new details on the following interesting projects for the GMP area:

  • A closer collaboration with PIC/S on guidelines with relevance to both Regulatory Assessor and  Inspector disciplines is being planned.
    PIC/S would be involved in ICH Guideline work during the public consultation following Step 2band additionally, as an ICH Observer, PIC/S could also request to be part of Plenary Working Parties (PWPs) which would allow an involvement prior to Step 1. The Assembly supported the development of a pilot process.
     
  • On her part, the WHO is planning to cooperate with the ICH.
    The Assembly noted WHO’s considerations shared on the areas of work and complementarities of ICH and WHO which should be considered in ICH Guideline development.
     
  • The Concept Paper outline on the revision of ICH Q9: Quality Risk Management was approved. Both, the ICH Assembly and Management Committee noted capacity constraints in the quality topic area. The starting time for the Q9(R1) guideline will therefore be delayed.
     
  • The Q3C(R8) Maintenance EWG continues its work on the development of Permitted Daily Exposure (PDE) levels for the solvents 2-methyltetrahydrofuran, cyclopentylmethylether and tert-butanol. Q3C(R8) is expected to reach Steps 1 and 2a/b by early 2020.
     
  • The Q3D(R2) Maintenance EWG continues its work on the draft Addendum on cutaneous and transdermal routes of administration.Steps 1 and 2a/b of the Q3D(R2) revision for the cutaneous and transdermal products are expected by early 2020.

The next meeting is scheduled from May 23-27, 2020 in Vancouver, Canada.


Source:

ICH: Meeting Minutes

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next